CAR T-cell Therapy: Cancer & Autoimmune Disease Treatment
- Chimeric antigen receptor (CAR) T-cell therapies have revolutionized the treatment of B cell malignancies.
- However, the widespread adoption of CAR T-cell therapy faces notable obstacles.The complex and costly manufacturing processes involved in creating these personalized treatments limit their availability.
- Researchers are actively working to streamline the manufacturing process and develop CAR T-cell therapies that do not require pre-treatment with chemotherapy.
CAR T-Cell Therapy Faces Hurdles Despite Successes
Chimeric antigen receptor (CAR) T-cell therapies have revolutionized the treatment of B cell malignancies. This innovative approach harnesses the power of the patient’s own immune system to target and destroy cancer cells.
However, the widespread adoption of CAR T-cell therapy faces notable obstacles.The complex and costly manufacturing processes involved in creating these personalized treatments limit their availability. Furthermore,the necessity for lymphodepleting chemotherapy,a harsh treatment that weakens the immune system before CAR T-cell infusion,restricts the number of patients who can safely undergo this therapy.
What’s next
Researchers are actively working to streamline the manufacturing process and develop CAR T-cell therapies that do not require pre-treatment with chemotherapy. These advancements could broaden access to this perhaps life-saving treatment for a wider range of cancer patients.